US Diagnostics Company buys into Jena
bm|t beteiligungsmanagement thueringen GmbH has sold its holdings in CLONDIAG chip technologies GmbH in Jena, enabling the American diagnostics company Inverness Medical Innovations Inc. to enter this area of business. Inverness is initially taking a total of 67% of the holdings, paying 3.1 million dollars for it as well as a shares package. On 31 August 2006, 4.9 million dollars will be paid for the remainder and for further shares. At the same time, the purchaser has undertaken obligations to a total of over 10 million dollars. “The sale of our holdings opens up various strategic options for the company”, stated bm|t managing director Dr Guido Bohnenkamp in Erfurt.
CLONDIAG was founded in 1998 and successfully develops and produces its own products for research and clinical diagnostics. Miniaturised, reliable diagnosis systems enable complex molecular biological analyses to be carried out very quickly, simply and economically. Thousands of tests in parallel are possible. The involvement of Inverness provides synergy effects and so opens up opportunities for more rapid and wider penetration of the market, particularly in the point-of-care area.
bm|t has been supporting CLONDIAG financially and in terms of business management since the end of 1999.
Inverness Medical Innovations has its headquarters in Waltham, Massachusetts and is a leading company worldwide in the production and sale of in vitro diagnosis products – for example, for pregnancy and fertility tests and other professional rapid tests for clinical diagnosis. In 2005, Inverness had an annual turnover of over 400 million dollars and employs around 1,700 staff. Its products are sold worldwide, particular targets being USA, Germany, France, Spain and Scandinavia.